- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01990391
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
November 20, 2013 updated by: Grazielle Vilas Boas Huguenin, Universidade Federal do Rio de Janeiro
Effect of Brazil Nut Consumption in the Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities in Hypertensive and Dyslipidemic Subjects
The purpose this research is to check the effect of Brazil Nuts consumption in oxidative stress, metabolic abnormalities and microvascular endothelial function dyslipidemic and hypertensive patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
125
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adults > 20 years old
- Dyslipidemic
- Hypertensive
Exclusion Criteria:
- Allergy to nuts
- Consumption of nuts or vitamins/minerals supplement
- Loss weight before the research
- pregnancy
- Kidney chronic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cassava flavored flour
The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
|
The Brazil nut group received 13g/day of Brazil nut flour during three months.
|
Experimental: Brazil nut flour
The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
|
The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antioxidant biomarker
Time Frame: Change from Baseline at 12 weeks.
|
Change from Baseline plasma Gluthathione Peroxidase activity (nmol/min/ml) at 12 weeks, samples were stocked at -80 degrees.
|
Change from Baseline at 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxidative stress biomarker
Time Frame: Change from Baseline at 12 weeks.
|
The change from baseline plasma 8-isoprostane (pg/ml) at 12 weeks, samples were stocked at -80 degrees.
|
Change from Baseline at 12 weeks.
|
microvascular endothelial function
Time Frame: Change from baseline at 12 weeks
|
Microvascular reactivity was evaluated using an Laser Speckle Contrast Imaging system with a laser wavelength of 785 nm in combination with the iontophoresis (increasing anodal currents of 30, 60, 90, 120, 150 and 180μA for 10 second intervals spaced 1 minute apart) of acetylcholine (2% v/v) for the noninvasive and continuous measurement of cutaneous microvascular perfusion changes measured in arbitrary perfusion units.
|
Change from baseline at 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anthropometric measures
Time Frame: Change from baseline at 12 weeks
|
body weight (kg), body mass index (kg/m2) and waist circumference (cm).
|
Change from baseline at 12 weeks
|
Blood lipids
Time Frame: Change from baseline at 12 weeks
|
total Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides (mg/dl).
|
Change from baseline at 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Grazielle V B Huguenin, Nutricionist, Universidade Federal do Rio de Janeiro
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Carvalho RF, Huguenin GV, Luiz RR, Moreira AS, Oliveira GM, Rosa G. Intake of partially defatted Brazil nut flour reduces serum cholesterol in hypercholesterolemic patients--a randomized controlled trial. Nutr J. 2015 Jun 16;14:59. doi: 10.1186/s12937-015-0036-x.
- Huguenin GV, Oliveira GM, Moreira AS, Saint'Pierre TD, Goncalves RA, Pinheiro-Mulder AR, Teodoro AJ, Luiz RR, Rosa G. Improvement of antioxidant status after Brazil nut intake in hypertensive and dyslipidemic subjects. Nutr J. 2015 May 29;14:54. doi: 10.1186/s12937-015-0043-y.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
November 10, 2013
First Submitted That Met QC Criteria
November 14, 2013
First Posted (Estimate)
November 21, 2013
Study Record Updates
Last Update Posted (Estimate)
November 25, 2013
Last Update Submitted That Met QC Criteria
November 20, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0008.0.197.185-11
- U1111-1132-2061 (Other Identifier: Universal trial number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Yooyoung Pharmaceutical Co., Ltd.CompletedCombined DyslipidemiaKorea, Republic of
-
Société des Produits Nestlé (SPN)CompletedPrimary DyslipidemiaChina
-
Provident Clinical ResearchReliant PharmaceuticalsUnknown
Clinical Trials on Brazil nut flour
-
Rio de Janeiro State UniversityCompleted
-
University of Sao PauloNewcastle University; Aix Marseille Université; University of AberdeenCompleted
-
Skogli Health and Rehabilitation CenterCompleted
-
University of GuamNational Cancer Institute (NCI); University of Hawaii Cancer Research CenterCompletedTobacco Cessation | Betel Nut ChewerGuam
-
University of Sao PauloCompleted
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of JenaRecruitingSelenium | Diet, VeganGermany
-
Northumbria UniversityInternational Nut and Dried Fruit CouncilCompletedCognitive Function | Intestinal Microbiota | Urinary MetabolitesUnited Kingdom
-
South Dakota State UniversityCompleted
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompleted